activated recombinant human factor VII + activated recombinant human factor VII
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Bleeding Disorder
Conditions
Acquired Bleeding Disorder, Acquired Haemophilia, Congenital Bleeding Disorder, Congenital FVII Deficiency, Glanzmann's Disease, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors, Healthy
Trial Timeline
Apr 1, 2006 → Sep 1, 2006
NCT ID
NCT01561417About activated recombinant human factor VII + activated recombinant human factor VII
activated recombinant human factor VII + activated recombinant human factor VII is a phase 1 stage product being developed by Novo Nordisk for Acquired Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01561417. Target conditions include Acquired Bleeding Disorder, Acquired Haemophilia, Congenital Bleeding Disorder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01561417 | Phase 1 | Completed |
| NCT01562587 | Phase 1 | Completed |
Competing Products
20 competing products in Acquired Bleeding Disorder